As of 2026-04-01, the Relative Valuation of Pharming Group NV (PHARM.AS) is 0.43 EUR. This relative valuation is based on P/E multiples. With the latest stock price at 1.43 EUR, the upside of Pharming Group NV based on Relative Valuation is -70.0%.
The range of the Relative Valuation is 0.20 - 0.76 EUR.
| Range | Selected | |
| Trailing P/E multiples | 49.9x - 71.6x | 60.8x |
| Forward P/E multiples | 34.3x - 52.9x | 43.0x |
| Fair Price | 0.20 - 0.76 | 0.43 |
| Upside | -86.0% - -47.2% | -70.0% |
| Date | P/E |
| 2026-03-31 | 351.94 |
| 2026-03-30 | 350.20 |
| 2026-03-27 | 353.43 |
| 2026-03-26 | 353.18 |
| 2026-03-25 | 349.46 |
| 2026-03-24 | 345.73 |
| 2026-03-23 | 339.52 |
| 2026-03-20 | 338.28 |
| 2026-03-19 | 329.84 |
| 2026-03-18 | 331.82 |
| 2026-03-17 | 333.07 |
| 2026-03-16 | 336.05 |
| 2026-03-13 | 321.14 |
| 2026-03-12 | 329.34 |
| 2026-03-11 | 341.01 |
| 2026-03-10 | 345.48 |
| 2026-03-09 | 338.03 |
| 2026-03-06 | 330.33 |
| 2026-03-05 | 335.55 |
| 2026-03-04 | 341.76 |
| 2026-03-03 | 334.56 |
| 2026-03-02 | 342.01 |
| 2026-02-27 | 345.98 |
| 2026-02-26 | 343.50 |
| 2026-02-25 | 358.40 |
| 2026-02-24 | 356.91 |
| 2026-02-23 | 348.46 |
| 2026-02-20 | 349.95 |
| 2026-02-19 | 350.20 |
| 2026-02-18 | 356.41 |
| 2026-02-17 | 341.26 |
| 2026-02-16 | 330.09 |
| 2026-02-13 | 330.58 |
| 2026-02-12 | 322.88 |
| 2026-02-11 | 329.59 |
| 2026-02-10 | 339.27 |
| 2026-02-09 | 342.01 |
| 2026-02-06 | 339.27 |
| 2026-02-05 | 347.72 |
| 2026-02-04 | 355.42 |
| 2026-02-03 | 361.38 |
| 2026-02-02 | 355.67 |
| 2026-01-30 | 425.21 |
| 2026-01-29 | 428.44 |
| 2026-01-28 | 424.71 |
| 2026-01-27 | 442.10 |
| 2026-01-26 | 424.96 |
| 2026-01-23 | 415.52 |
| 2026-01-22 | 419.75 |
| 2026-01-21 | 377.03 |